These EGFR-targeted tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib have shown improved tumor response and progression-free survival outcome in EGFR-mutated NSCLC compared with cytotoxic chemotherapies [7–9]. This evidence concerns the gene EGFR and neoplasm.